Takayama Naoya, Eto Koji
Clinical Application Department, Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan.
Methods Mol Biol. 2012;788:205-17. doi: 10.1007/978-1-61779-307-3_15.
Human embryonic stem cells (hESCs) represent a potential source of blood cells for transfusion therapies and a promising tool for studying the ontogeny of hematopoiesis. Moreover, human-induced pluripotent stem cells (hiPSCs), recently established by defined reprogramming factors expressed in somatic cells, represent a further source for the generation of hematopoietic cells. When undifferentiated hESCs or hiPSCs are cultured on either mesenchymal C3H10T1/2 cells or OP-9 stromal cells, they can be differentiated into a hematopoietic niche that concentrates hematopoietic progenitors, which we named "embryonic stem cell-derived sacs" (ES-sacs). We have optimized the in vitro culture condition for obtaining mature megakaryocytes derived from the hematopoietic progenitors within ES-sacs, which are then able to release platelets. These in vitro-generated platelets display integrin activation capability, indicating normal hemostatic function. This novel protocol thus provides a means of generating platelets from hESCs as well as hiPSCs, for the study of normal human thrombopoiesis and also thrombopoiesis in disease conditions using patient-specific hiPSCs.
人类胚胎干细胞(hESCs)是输血治疗中血细胞的潜在来源,也是研究造血发生的有前景的工具。此外,最近通过在体细胞中表达的特定重编程因子建立的人类诱导多能干细胞(hiPSCs),是产生造血细胞的另一个来源。当未分化的hESCs或hiPSCs在间充质C3H10T1/2细胞或OP-9基质细胞上培养时,它们可以分化成一个造血微环境,该微环境聚集造血祖细胞,我们将其命名为“胚胎干细胞衍生囊”(ES-囊)。我们优化了体外培养条件,以获得源自ES-囊内造血祖细胞的成熟巨核细胞,这些巨核细胞随后能够释放血小板。这些体外生成的血小板具有整合素激活能力,表明具有正常的止血功能。因此,这种新方法提供了一种从hESCs以及hiPSCs生成血小板的方法,用于研究正常人类血小板生成以及使用患者特异性hiPSCs研究疾病状态下的血小板生成。